Form 4: Bioxytran Director Radka Milanova Acquires Shares in Open Market Transaction

Bioxytran director Radka Milanova acquired 97,535 shares of common stock at a price of $0.315 per share on January 6, 2025.

Summary

• Radka Milanova, a director at Bioxytran, Inc., acquired 97,535 shares of the company's common stock on January 6, 2025.
• The shares were purchased at a price of $0.315 per share.
• Following the transaction, Ms. Milanova directly owns 154,683 shares of Bioxytran stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the purchase indicates confidence from a director, it's a single transaction and doesn't provide a comprehensive view of the company's performance.

Positives

• The director's purchase of shares could be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
• The transaction is typical of insider trading activity, where directors and officers buy or sell shares of their company.
• The reporting requirements are consistent across all companies listed on US exchanges.

Stakeholder Impact

• The share purchase may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Bioxytran, BIXT, insider trading, share acquisition, director, Radka Milanova, SEC Form 4